Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning

Multiple Sclerosis

Volumn 22, Issue 11, 2016, Pages 1506-1508

  Martinelli, Vittorio ^a   Colombo, Bruno ^a   Dalla Costa, Gloria ^a   Dalla Libera, Dacia ^a   Moiola, Lucia ^a   Falini, Andrea ^a   Comi, Giancarlo ^a   Filippi, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY; STEROID;

ADOLESCENT; CASE REPORT; DISEASE ACTIVITY; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HYPESTHESIA; LETTER; LOWER LIMB PARESTHESIA; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PREGNANCY; RECURRENT DISEASE; RELAPSE; BRAIN; CHRONIC DISEASE; PATHOLOGY; TREATMENT OUTCOME; BRAIN DAMAGE; CLINICAL ARTICLE; CONCEPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; LOWER LIMB; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REBOUND;

ADOLESCENT; BRAIN; CHRONIC DISEASE; FEMALE; HUMANS; MULTIPLE SCLEROSIS; NATALIZUMAB; PREGNANCY; RECURRENCE; TREATMENT OUTCOME;

EID: 84989917674     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513492246     Document Type: Letter

References (10)

1. Cree B, De Seze J, Fox R, et al. RESTORE Study: Effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis Magnetic Resonance Imaging disease activity. Neurology 2012; 78: P 06.168
2. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865.
3. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70: 1150-1151. Epub ahead of publication 13 2007.
4. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: Poorly tolerated. Ann Neurol 2010; 68: 392-395.
5. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice G, for the international natalizumab multiple sclerosis trial group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
6. Borriello G, Prosperini L, Marinelli F, Fubelli F, Pozzilli C,. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 2011; 17: 372-5.
7. West TW, Cree B,. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68: 395-9.
8. Miravalle A, Jensen R, Kinkel P,. Immune reconstitution inflammatory symdrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68: 186-91.
9. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011; 308: 98-102.
10. Hellwig K, Haghikia A, Gold R, Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011; 17: 958-963.